Related Experiment Video

Updated: Jun 20, 2026

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

Poly(ADP-ribose) polymerase inhibition in cancer therapy: are we close to maturity?

Gianluca Papeo1, Barbara Forte, Paolo Orsini

  • 1Department of Medicinal Chemistry, Nerviano Medical Sciences, Viale Pasteur 10, Nerviano (MI), Italy.

Expert Opinion on Therapeutic Patents
|September 12, 2009
PubMed
Abstract

Insights

Poly(ADP-ribose) polymerase (PARP) inhibitors are increasingly used in cancer therapy. Recent advancements show promising orally available PARP-1 inhibitors for specific cancer types and new therapeutic targets.

Area of Science:

  • Oncology
  • Pharmacology
  • Biochemistry

Background:

  • Poly(ADP-ribose) polymerase (PARP) inhibitors are gaining prominence in cancer treatment.
  • Increased understanding of PARP-1 function and clinical benefits of its inhibition drives this trend.

Purpose of the Study:

  • To provide an update on PARP inhibition in cancer therapy.
  • Review recent scientific and patent literature from 2005-2008.

Main Methods:

  • Comprehensive literature search of scientific databases (SciFinder).
  • Patent literature review (Chemical Abstract/Derwent).

Main Results:

  • Emergence of orally available PARP-1 inhibitor clinical candidates.
  • Identification of specific molecularly defined cancer indications for PARP-1 inhibitors as single agents.

Conclusions:

  • Orally available PARP-1 inhibitors enhance patient compliance and offer new therapeutic options.
  • Other PARP family members, like Tankyrase 1, represent potential future drug targets.
  • Novel PARP inhibitor compounds are being developed, expanding beyond traditional NAD-mimicking structures.

More Related Videos

Utilization of the Soft Agar Colony Formation Assay to Identify Inhibitors of Tumorigenicity in Breast Cancer Cells11:06

Utilization of the Soft Agar Colony Formation Assay to Identify Inhibitors of Tumorigenicity in Breast Cancer Cells

Published on: May 20, 2015

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
DNA Damage can Stall the Cell Cycle02:36

DNA Damage can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
DNA Damage Can Stall the Cell Cycle02:36

DNA Damage Can Stall the Cell Cycle

In response to DNA damage, cells can pause the cell cycle to assess and repair the breaks. However, the cell must check the DNA at certain critical stages during the cell cycle. If the cell cycle pauses before DNA replication, the cells will contain twice the amount of DNA. On the other hand, if cells arrest after DNA replication but before mitosis, they will contain four times the normal amount of DNA. With a host of specialized proteins at their disposal,cells must use the right protein at...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.